Quick Answer
Solid Biosciences Inc. reported Stockholders Equity of $180.01 million for the year ending 2025.
- Solid Biosciences Inc. showed an increase of +31.2% in Stockholders Equity from 2024 to 2025.
- This data is from Solid Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: -$59.26 million | Q1 2018: $178.95 million | Q2 2018: $162.29 million | Q3 2018: $145.07 million | Q4 2018: $125.18 million | Q1 2019: $99.11 million | Q2 2019: $76.50 million | Q3 2019: $108.53 million | Q4 2019: $80.05 million | Q1 2020: $56.46 million | Q2 2020: $40.71 million | Q3 2020: $22.23 million | Q4 2020: $132.09 million | Q1 2021: $253.00 million | Q2 2021: $237.94 million | Q3 2021: $223.36 million | Q4 2021: $208.21 million | Q1 2022: $185.51 million | Q2 2022: $162.24 million | Q3 2022: $143.28 million | Q1 2023: $183.79 million | Q2 2023: $163.73 million | Q3 2023: $144.36 million | Q1 2024: $210.72 million | Q2 2024: $193.25 million | Q3 2024: $167.02 million | Q1 2025: $294.46 million | Q2 2025: $258.29 million | Q3 2025: $217.95 million.
- Over the full 8 years of available data (2018 to 2025), Solid Biosciences Inc.'s Stockholders Equity has grown by 43.8%.
- Historical annual values: Fiscal year 2025: $180.01 million | Fiscal year 2024: $137.25 million | Fiscal year 2023: $126.48 million | Fiscal year 2022: $211.67 million | Fiscal year 2021: $208.21 million | Fiscal year 2020: $132.09 million | Fiscal year 2019: $80.05 million | Fiscal year 2018: $125.18 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: